4'-溴-4-氯苯丁酮 | 4559-96-0

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酮
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4'-溴-4-氯苯丁酮
• 中文别名: 4’-溴-4-氯苯丁酮；4-溴-4-氯苯丁酮；4′-溴-4-氯苯丁酮；4"-溴-4-氯苯丁酮
• 英文名称: 1-(4-bromophenyl)-4-chlorobutan-1-one
• 英文别名: 4'-bromo-4-chlorobutyrophenone；4-bromo-γ-chlorobutyrophenone
• CAS: 4559-96-0
• 化学式: C₁₀H₁₀BrClO
• mdl: MFCD00001006
• 分子量: 261.546
• InChiKey: WJKPUMBLABGUCQ-UHFFFAOYSA-N

物化性质

• 熔点：
  35.5-38 °C(lit.)
• 沸点：
  150-157 °C(Press: 6.5 Torr)
• 密度：
  1.4780 (rough estimate)
• 闪点：
  >230 °F
• 稳定性/保质期：

  在常温常压下，该物质保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  常温、避光、通风干燥处，密封保存。

SDS

Name:	4 -Bromo-4-Chlorobutyrophenone 99% Material Safety Data Sheet
Synonym:	1-(4-Bromophenyl)-4-Chloro-1-Butanon
CAS:	4559-96-0

Section 1 - Chemical Product MSDS Name:4 -Bromo-4-Chlorobutyrophenone 99% Material Safety Data Sheet
Synonym:1-(4-Bromophenyl)-4-Chloro-1-Butanon

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4559-96-0	4'-Bromo-4-Chlorobutyrophenone	99	224-930-3

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 4559-96-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: cream
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 35.50 - 38.00 deg C
Autoignition Temperature: Not available.
Flash Point: > 110 deg C (> 230.00 deg F)
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10BrClO
Molecular Weight: 261.54

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4559-96-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4'-Bromo-4-Chlorobutyrophenone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 4559-96-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 4559-96-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4559-96-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4'-溴-4-氯苯丁酮 在 六甲基磷酰三胺 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 硫酸 、 silver(l) oxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 49.0h， 生成 2-(4-Bromophenyl)-5-(chloromethyl)thiophene
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents

  摘要：

  5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)- thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate acid (5d), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.08.009
• 作为产物：
  描述：

  1-(4-溴苯基)环丁醇 在 manganese(II) triflate 、 lithium perchlorate 、 溶剂黄146 、 magnesium chloride 作用下， 以 乙腈 为溶剂， 反应 3.5h， 以73%的产率得到4'-溴-4-氯苯丁酮
  参考文献：
  名称：

  锰催化的烷氧基自由基对环烷醇的电化学解构氯化反应。

  摘要：

  已经开发了锰催化的环烷醇的电化学解构氯化法。这种电化学方法可从醇中获得烷氧基，并具有广泛的底物范围，可将各种环丙醇和环丁醇转化为可合成使用的β-和γ-氯化酮（40个实例）。此外，采用循环流电化学和连续在线纯化的组合以克为单位获得产物。

  DOI：

  10.1021/acs.orglett.9b03652

文献信息

• Process for preparation of benzo[f]quinolinones
  申请人：Eli Lilly and Company

  公开号：US05578724A1

  公开（公告）日：1996-11-26

  A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase and their preparation is disclosed.

  一系列苯醌啉-3-酮类药物在治疗由I型和II型5α-还原酶引起的疾病方面具有有效性，并且其制备方法已被披露。
• 2-PYRIDONE COMPOUNDS
  申请人：KAWAGUCHI Takanori

  公开号：US20110237791A1

  公开（公告）日：2011-09-29

  A 2-pyridone compound represented by the formula [1]: wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.

  化学式为[1]所代表的2-吡啶酮化合物： 其中在化学式[1]中， 由A代表苯环或吡啶环表示的环， X代表下面所示的化学式[3]所代表的任意结构： V代表单键或较低的烷基链，以及 W代表单键、醚键或较低的烷基链（其中较低的烷基链可能含有醚键）}， 该化合物的异构体或立体异构体，其药学上可接受的盐，或其溶剂化合物是一种具有出色的GK激活效果并且可用作药物的化合物。
• 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
  申请人：Zhang Puwen

  公开号：US20070066628A1

  公开（公告）日：2007-03-22

  Compounds of formula I are provided, wherein R 1 -R 9 and n are defined herein, and pharmaceutical compositions and kits containing these compounds. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R 3 -R 5 , R 10 , and R 11 are defined herein.

  提供了式I的化合物，其中R1-R9和n在此处定义，并且含有这些化合物的药物组合物和试剂盒。 还提供了使用式I或式II的化合物诱导避孕、提供激素替代疗法、治疗与周期相关的症状，或治疗或预防良性或恶性肿瘤疾病的方法，其中R3-R5、R10和R11在此处定义。
• NPY antagonists: spiroisoquinolinone derivatives
  申请人：Bristol-Myers Squibb Company

  公开号：US06348472B1

  公开（公告）日：2002-02-19

  A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of spiroisoquinolinone derivatives of Formula I. As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.

  一系列非肽类NPY拮抗剂已经合成，由式I的螺环异喹啉酮衍生物组成。 作为NPY诱导的进食行为的拮抗剂，预计这些化合物和已知类似物将作为有效的厌食剂，在促进减重和治疗进食障碍方面发挥作用。
• Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
  申请人：eFFECTOR THERAPEUTICS, INC.

  公开号：US10112955B2

  公开（公告）日：2018-10-30

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A1, A2, A3, A4, A5, W1, Y, R1, R2, R3, R4, R5, R6a, R6b, R7, R8, R8a, R8b, R9, R9a, R9b, and R10 and subscript “n” are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了根据式I合成的化合物、药用可接受的配方和用途，或其立体异构体、互变异构体或药用可接受的盐。 对于式I中的化合物A1、A2、A3、A4、A5、W1、Y、R1、R2、R3、R4、R5、R6a、R6b、R7、R8、R8a、R8b、R9、R9a、R9b和R10以及下标“n”，如规范中所定义。创新的式I化合物是Mnk的抑制剂，并在许多治疗应用中发挥作用，包括但不限于治疗炎症和各种癌症。